London, 01 February 2021 – Leading global oncology provider, GenesisCare, has today announced the appointment of Justin Hely as its new UK General Manager. Justin joins GenesisCare with 20 years’ experience in both UK and international healthcare markets; he will take over the role from James McArthur, who has moved internally into a global role.
Justin began his career in the NHS before joining EY, where he advised a range of clients on operational and strategic improvement programmes. Prior to this, during his time with BMI Healthcare, he led several private acute hospitals working at Board and Executive Committee level. In his most recent role at healthcare and life science consultancy, Akeso & Company, Justin was responsible for bringing growth opportunities and operational excellence to healthcare providers.
Justin will work closely with the GenesisCare UK and global teams, independent care providers and external shareholders to help guide the expansion of the organisation’s clinics and treatment centres across the UK. He will drive new initiatives and access programs to ensure GenesisCare continues to deliver world-class patient-centric care as one of the top 1 per cent of healthcare providers globally.
In the past 24 months, GenesisCare has added two new centres to its network with the opening of an advanced radiotherapy centre in Bristol and the launch of Europe’s most advanced radiotherapy centre in London Cromwell Hospital, offering patients access to the MRIdian MR-Linac, Gamma Knife Icon and Varian Edge Linac. In addition to investing in two new sites, GenesisCare has introduced a number of innovative oncology services and technology, including ViewRay’s MRIdian MR-Guided Linac, Stereotactic Radiosurgery (SRS), Theranostics and the national roll out of spacing gel which is provided as standard for all our prostate patients.
Justin joins GenesisCare at a important time: strong, long term relationships with major healthcare insurers are in place, and a raft of digital innovations are being launched to streamline clinical referral processes whilst providing robust governance and oversight of safety and quality procedures.
GenesisCare’s Global Chief Operating Officer, Michael O’Sullivan comments: “We are delighted to welcome Justin as GenesisCare’s new UK General Manager who will play a crucial role in guiding the strategic direction of GenesisCare in the UK. Justin’s impressive record of leadership, innovation and growth, combined with the wealth of healthcare experience he brings, will provide a unique and fresh perspective as we continue to expand and invest in new services and technology in the UK.”
Newly appointed UK General Manager, Justin Hely, adds: “I am truly excited by the opportunity this role brings and look forward to leading the organisation as it expands its portfolio in the coming years. Access to high-quality healthcare has never been more important, and I’m delighted to join the GenesisCare team who are committed to providing patients with the best life outcomes through outstanding care and treatment.
“I am particularly excited by the integrated pathways GenesisCare provides – from one-stop diagnostics, through to chemotherapy and radiotherapy treatments supported by exercise medicine, holistic treatments and counselling are carried through a patient’s treatment journey,” said Mr Hely.
For further information please contact:
More information about GenesisCare can be found on the website www.gensiscare.com/uk/
About GenesisCare in the UK
GenesisCare is one of the UK’s leading independent providers of advanced and innovative cancer diagnostics, chemotherapy, radiotherapy and Theranostics. It currently operates 14 specialist oncology outpatient centres across the country, including two new centres; the advanced radiotherapy centre in Bristol and Europe’s most advanced radiotherapy treatment centre at the Cromwell Hospital in London. With a focus on evidence-based therapies GenesisCare pioneers’ treatment on state-of-the-art machinery and patient pathways including the MRIdian Linac and SABR to ensure care experiences that allow for the best possible life outcomes. We are consistently rated over 90% for patient satisfaction.